Rivaroxaban Combined With DAPT Versus DAPT Alone After Drug-coated Balloon Angioplasty - Trial NCT05750758
Access comprehensive clinical trial information for NCT05750758 through Pure Global AI's free database. This phase not specified trial is sponsored by Henan Institute of Cardiovascular Epidemiology and is currently Not yet recruiting. The study focuses on Acute Coronary Syndrome. Target enrollment is 120 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Henan Institute of Cardiovascular Epidemiology
Timeline & Enrollment
N/A
Feb 20, 2023
Apr 01, 2024
Primary Outcome
Loss of lumen area of target vessel
Summary
The target population of this interventional study was ACS patients with drug-coated
 balloons. The main discussion : 1.1 months of rivaroxaban combined with dual antiplatelet
 therapy compared with dual antiplatelet therapy alone, late lumen loss at 6 months. 2. To
 determine the safety of the regimen with bleeding events as the end point. Subjects were
 randomly assigned to two groups, one receiving routine DAPT for six months and one receiving
 DAPT plus one month of rivaroxaban 2.5 mg bid
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05750758
Non-Device Trial